Keywords: Biogen Idec, Elan, Tysabri, FDA, EMA, Multiple sclerosis, PML
Biogen and Elan seek additional labeling for MS drug Tysabri to test for PML
Article | 23 December 2010
USA-based Biogen Idec (Nasdaq: BIIB) and Irish marketing partner Elan (NYSE: ELN) have submitted a supplemental Biologics License Application to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
